SSB’s Ambr Bioreactor Systems Enhanced with Software for Design of Experiments

Ambr Sartorius SSB

The French company, Sartorius Stedim Biotech (SSB), announced that the 2015 version of the Ambr systems (Ambr 15 and Ambr 250) will be supplied with integrated BioPAT MODDE Software for Design of Experiments (DoE), powered by Umetrics. This will allow bioprocess scientists to easily implement DoE into their work flow for simpler process optimization and scale-up to larger single-use BIOSTAT pilot and manufacturing scale bioreactors, making bioprocess development faster and more cost-effective.

The integrated DoE software will enable scientists to quickly establish a Design Space where relevant bioprocessing conditions are varied simultaneously. Users can rapidly configure DoE experiments via work packets that are exported from the software to the Ambr system. This way, it is possible to configure each micro bioreactor with its own DoE defined bioprocessing parameters. The data generated from Ambr, including offline analytics, is analyzed within the software to identify critical process parameters, optimize bioprocessing conditions and define a robust design space for implementation in larger single-use BIOSTAT pilot and manufacturing scale bioreactors.

Dr. Barney Zoro, Ambr15 Product Manager at SSB commented: “To facilitate greater implementation of DoE across the industry we have combined the power of Ambr with the BioPAT MODDE software. These synergistic technologies are ideally suited for media optimization and process parameter screening applications. Additionally, the software can be used for Monte Carlo Simulations as part of a Quality by Design (QbD) programme to identify the desired operating region for manufacturing scale processes, to make scale-up quicker and simpler.

SSB’s goal is to ensure that bioprocess scientists can develop their processes as quickly as possible. Ultimately, implementing this approach will contribute to biotech and pharma firms reducing risk in bioprocess development and achieving more rapid, cost-effective production of their biologics and vaccines.

Explore other topics: BioinformaticsFrance

Newsletter Signup - Under Article

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More